Avidity Partners Management LP
Avidity Partners Management LP reported 18 holdings worth US$488M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Avidity Partners Management LP reported 18 holdings worth US$488M as of Sep 30, 2026. Largest: Dianthus Therapeutics, Inc., CG Oncology, Inc. and Oruka Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 18
- Value as reported
- US$488M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Dianthus Therapeutics, Inc. | 1.9M | US$167M | 34.3% |
| CG Oncology, Inc. | 1.35M | US$95.6M | 19.6% |
| Oruka Therapeutics, Inc. | 785K | US$65.4M | 13.4% |
| Jade Biosciences, Inc. | 2M | US$28.1M | 5.8% |
| Enliven Therapeutics, Inc. | 550K | US$25.2M | 5.2% |
| Perspective Therapeutics, Inc. | 6.07M | US$16.7M | 3.4% |
| Aktis Oncology, Inc. | 484K | US$9.43M | 1.9% |
| Immunic, Inc. | 670K | US$6.23M | 1.3% |
| Mobia Medical, Inc. | 325K | US$3.07M | 0.63% |
| Palvella Therapeutics, Inc. | 20,000 | US$2.76M | 0.57% |
| Nuvectis Pharma, Inc. | 100K | US$2.12M | 0.43% |
| Satellos Bioscience Inc | 164K | US$1.39M | 0.29% |
| Context Therapeutics Inc. | 4.06M | US$1.22M | 0.25% |
| Karyopharm Therapeutics Inc. | 885K | US$1.08M | 0.22% |
| Senseonics Holdings, Inc. | 100K | US$1.02M | 0.21% |
| Avalyn Pharma Inc. | 20,000 | US$570K | 0.12% |
| Genmab A/S | 0 | US$0 | 0.00% |
| Gilead Sciences, Inc. | 0 | US$0 | 0.00% |
| Insulet Corporation | 0 | US$0 | 0.00% |
| Intellia Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Kailera Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Peloton Interactive, Inc. | 0 | US$0 | 0.00% |
| Phathom Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Repligen Corporation | 0 | US$0 | 0.00% |
| Savara, Inc. | 0 | US$0 | 0.00% |
| Tempus AI, Inc. | 0 | US$0 | 0.00% |
| Tenax Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Teva Pharmaceutical Industries Limited | 0 | US$0 | 0.00% |
| Trevi Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Vir Biotechnology, Inc. | 0 | US$0 | 0.00% |
| Abbott Laboratories | 0 | US$0 | 0.00% |
| Alamar Biosciences, Inc. | 0 | US$0 | 0.00% |
| Boston Scientific Corporation | 0 | US$0 | 0.00% |
| BridgeBio Oncology Therapeutics, Inc. | 0 | US$0 | 0.00% |
| BridgeBio Pharma, Inc. | 0 | US$0 | 0.00% |
| Charles River Laboratories International, Inc. | 0 | US$0 | 0.00% |
| Corvus Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| DexCom, Inc. | 0 | US$0 | 0.00% |
| Encompass Health Corporation | 0 | US$0 | 0.00% |
| Evommune, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related